Journal
DIABETIC MEDICINE
Volume 30, Issue 1, Pages 46-55Publisher
WILEY
DOI: 10.1111/j.1464-5491.2012.03750.x
Keywords
-
Categories
Funding
- Abbott
- GSK
- Roche
- Consultant Board of GSK
- Daiichi-Sankoyo
- Pfizer
- DPPOS
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health
- NIDDK
- Indian Health Service
- National Institute of Child Health and Human Development
- National Institute on Aging
- National Eye Institute
- National Heart Lung and Blood Institute
- Office of Research on Women's Health
- National Center for Minority Health and Human Disease
- Centers for Disease Control and Prevention
- American Diabetes Association
- Bristol-Myers Squibb
- Parke-Davis
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079637, P30DK072476, U01DK048406, ZIADK075078, U01DK048489, P30DK017047] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Diabet. Med. 30, 4655 (2013) Abstract Aims Whether long-term cardiovascular risk is reduced by the Diabetes Prevention Program interventions is unknown. The aim of this study was to determine the long-term differences in cardiovascular disease risk factors and the use of lipid and blood pressure medications by the original Diabetes Prevention Program intervention group. Methods This long-term follow-up (median 10 years, interquartile range 9.010.5) of the three-arm Diabetes Prevention Program randomized controlled clinical trial (metformin, intensive lifestyle and placebo), performed on 2766 (88%) of the Diabetes Prevention Program participants (who originally had impaired glucose tolerance), comprised a mean of 3.2 years of randomized treatment, approximately 1-year transition (during which all participants were offered intensive lifestyle intervention) and 5 years follow-up (Diabetes Prevention Program Outcomes Study). During the study, participants were followed in their original groups with their clinical care being provided by practitioners outside the research setting. The study determined lipoprotein profiles and blood pressure and medication use annually. Results After 10 years follow-up from Diabetes Prevention Program baseline, major reductions were seen for systolic (-2 to -3) and diastolic (-6 to -6.5 mmHg) blood pressure, and for LDL cholesterol (-0.51 to -0.6 mmol/l) and triglycerides (-0.23 to -0.25 mmol/l) in all groups, with no between-group differences. HDL cholesterol also rose significantly (0.14 to 0.15 mmol/l) in all groups. Lipid (P = 0.01) and blood pressure (P = 0.09) medication use, however, were lower for the lifestyle group during the Diabetes Prevention Program Outcomes Study. Conclusion Overall, intensive lifestyle intervention achieved, with less medication, a comparable long-term effect on cardiovascular disease risk factors, to that seen in the metformin and placebo groups. Diabet. Med. 30, 46-55 (2013)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available